Table 3 Serious adverse events due to protocol treatment in the sorafenib group and the HAIC group
Sorafenib group (n = 33) | HAIC group (n = 35) | ||
|---|---|---|---|
HAIC | sorafenib | ||
(n = 23) | |||
Adverse events | Grade 3/4 | Grade 3/4 | |
n (%) | n (%) | ||
Non-hematological | |||
Mucositis oral | 1 (3) | 1 (4) | |
Hoarseness | 0 (0) | 1 (4) | |
Hand-foot skin reaction | 5 (15) | 6 (26) | |
Rash | 2 (6) | 0 (0) | |
Anorexia | 1 (3) | 2 (9) | |
Diarrhea | 1 (3) | 0 (0) | |
Bleeding | 1 (3) | 1 (4) | |
Fatigue | 1 (3) | 1 (4) | |
Hypertension | 6 (18) | 8 (35) | |
Somnolence | 1 (3) | 0 (0) | |
Weight loss | 1 (3) | 0 (0) | |
Abdominal distension | 0 (0) | 1 (4) | |
Encephalopathy | 0 (0) | 1 (3) | 0 (0) |
Nausea | 0 (0) | 1 (3) | 0 (0) |
Hiccups | 0 (0) | 1 (3) | 0 (0) |
Absence seizure | 0 (0) | 1 (3) | 0 (0) |
Hydrocele testis | 0 (0) | 1 (3) | 0 (0) |
Hematological | |||
Thrombocytopenia | 3 (9) | 0 (0) | |
Transaminase elevation | 7 (21) | 3 (9) | 6 (26) |
Total bilirubin elevation | 2 (6) | 1 (3) | 2 (9) |
Creatinine elevation | 0 (0) | 0 (0) | |
Amylase elevation | 1 (3) | 0 (0) | |
Lipase elevation | 9 (27) | 4 (17) | |
Liver failure | 1 (3) | 0 (0) | |
Hypoalbuminemia | 0 (0) | 1 (4) | |
Hyponatremia | 1 (3) | 0 (0) | |
Hypophosphatemia | 2 (6) | 0 (0) | |
Others | |||
Portal thrombosis | 0 (0) | 1 (3) | 0 (0) |